
TSE:TSU
This summary was created by AI, based on 6 opinions in the last 12 months.
The Trisura Group (TSU-T) has faced stock price declines recently, which experts believe are unwarranted given the company's strong performance metrics and growth potential. With a book value that has increased by 20% year over year, surpassing $1 billion, and an exceptional combined ratio of under 85%, the company demonstrates healthy financial fundamentals. Amidst volatility in the insurance sector, Trisura has remained resilient, particularly in specialty insurance, focusing on expanding its market share in the U.S. Analysts highlight its solid management, strong cash position, and attractive valuation, suggesting it may become a compelling growth story once more. Despite recent challenges, the outlook remains optimistic for the company’s future performance and potential acquisition interest.
EPS of 65c matched estimates; Revenue of $772M was nicely ahead of estimates. Operating ROE was 19.6% vs 19% expected. Sales rose 16%. Net investment income rose 42%. Book value increased 26.3% to $14.56. Operating ratio was 87.5%. Scotia raised its priced target from $62 to $63. We would consider the results good.
Unlock Premium - Try 5i Free
Specialty insurance company with large US book. Volatile stock, but will continue to hold shares. Well run company. High growth company. Insurance lines can product write downs, but management teams learning from mistakes. Expecting growth multiple to grow. Expecting all time stock highs going forward.
EPS of $0.31 missed expectations of $0.4229 and revenues of $769.94M beat estimates of $758.69M. Insurance revenue grew by 32.7% in the quarter, reflecting sustained momentum across North America. Its operating net income was up 50.2%, driven by profitable growth in Canada and core operations in the US. Its net income was impacted by the run-off of a US program and unrealized losses in the investment portfolio, partially offset by one-time benefits in the primary lines business. Its net investment income grew substantially, due to higher risk-adjusted yields and an increased size of the investment portfolio. Its operating ROE of 20.2% exceeded its target, demonstrating the strength of its core operations. Its EPS estimates jump from FY2023 to FY2024 on a GAAP basis, however, non-GAAP, this EPS estimate goes from $2.40 to $2.64. Its balance sheet expanded, it has been issuing less shares than in previous quarters, and shares increased following results, indicating that investors are largely pleased with the results.
Its write-downs are still looming, but its core operations have shown strength and we think it begins to demonstrate its ability to execute and grow in future quarters.
Unlock Premium - Try 5i Free
Has followed business for a long term. Small cap insurance provider that has lots of room for growth. Massive growth the past few years. Taking lessons learned in Canada into the US market. Current share price a great place to buy. Problems from the past year being fixed very quickly. Higher interest rates not presenting problem for the company with cash flow.
Really likes insurance names. Financials have been under pressure, especially in the US. But US insurance names are doing really well. It's turning up, improving. Higher for longer should be a tailwind. Important support level around $30, so limit risk to recent lows. $36 and $42 are next major resistance levels.
Highly profitable with one of the highest combined ratios in Canada, and are very profitable in the U.S. Expects them to keep generating returns in the high-teens. Can keep growing for years to come. Trades at an attractive multiple. Could be taken out in the insurance space.
(Analysts’ price target is $57.86)